HAVN Life Sciences Aktie

Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2002, HAVN Life Sciences Aktie has already paid €3.81 in dividends. The last payout was in January 2002.

Financials

In the last year, HAVN Life Sciences Aktie had revenue of €204.15k and net profit of -€16.57m

(EUR)	2022	YoY
Revenue	204.15k	-
Gross profit	66.23k	102.12%
Net profit	-16.57m	19.42%
EBITDA	-5.47m	45.61%

Fundamentals

Metric	Value
Market capitalization	€2.29k
Number of shares	25.65m
52-week high/low	€0.00893 - €0.0000089
Dividends	No
Beta	-0.30
P/E ratio	-0.01
PEG ratio	0.00
P/B ratio	0.04
P/S ratio	4.17

Company profile

HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psilocin, and baeocystin, as well as the development of natural health care products from non-regulated compounds. The company was incorporated in 2020 and is headquartered in Richmond, Canada.